DP
About
Building on a robust foundation of proprietary peptide research and strategic collaborations, D&D Pharmatech is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The global biotech company’s umbrella structure comprises three U.S. subsidiaries, including Neuraly Inc, its clinical research arm responsible for conducting clinical trials for the company’s pipeline including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 116 investors are based in Seongnam, Kyonggi-do, South Korea.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Stages
- late-stage
- Sectors
- healthtech biotech
- Location
- Seongnam, South Korea
Contact Information
linkedin.com/in/••••••••
Find more investors like D&D
Search Investors